Month: January 2022

Bigben                                                Press release            Lesquin, 24 January 2022 – 18:00 RETURN TO GROWTH FOR Q3 2021/22 (+4,5%) CONFIRMATION OF 2021/22 & 2022/23 TARGETS        IFRS – M€ 2021/222020/21ChangeSales1st Half-year (April – Sept.) 124.2 135.8 -8.5%       Nacon Gaming 73.0 86.6 -15.7%Bigben Audio / Telco 51.2 49.2 +4.1%       3rdQuarter (Oct. – Déc.) (1) 91.3 87.3 +4.5%       Nacon Gaming 51.2 48.6 +5.2%Bigben AudioVideo / Telco 40.1 38.7 +3.5%       Cumulative 9 months (Apr. – Dec.) (1) 215.4 223.1 -3.4%       Nacon Gaming 124.2 135.3 -8.2%Bigben AudioVideo / Telco 91.2 87.8 +3.9%       (1)   Non audited data Highlights:As expected, the 3rd quarter of FY 2021/22 returned to growth after a first half impacted by a high comparison...

Company AnnouncementNo. 6/2022           Copenhagen, 24 January 2022 Scandinavian Tobacco Group’s Board of Directors intends to elect Henrik Brandt as Chairman as Nigel Northridge has decided to retire at the next Annual General Meeting Nigel Northridge, Chairman of the Board of Directors of Scandinavian Tobacco Group A/S, has informed the Board of Directors that he will not stand for re-election at the Annual General Meeting on 31 March 2022. Nigel Northridge joined the Board of Directors in 2016 and has been Chairman of the Board of Directors since 2017. Subject to the elections at the Annual General Meeting in March 2022, the Board of Directors will elect Henrik Brandt as the new Chairman of the Board of Directors. Henrik Brandt joined the Board in 2017 as Vice-chairman. Vice-chairman Henrik Brandt says: “Nigel has been the...

2021 TURNOVER EXCEPTIONAL LEVEL OF €184.1 MILLION • Continued growth in non-COVID activities (+14%)• Share of proprietary products increasing to 25%• Limited decline in COVID activities (-12%) in a context of sharp price declines• Record level of cash at more than 100 M euros Paris, January 24, 2022 – 5:45pm Eurobio Scientific (FR0013240934, ALERS, PEA-PME eligible), a leading French group in in vitro medical diagnostics and life sciences, today presents its consolidated annual revenue as of December 31, 2021. Maintaining a high level of activity Eurobio Scientific recorded revenues of €184.1 million in 2021, close to the record level set in 2020. In a year still very dependent on the COVID health crisis, these figures reflect:A still very high level of sales related to COVID diagnosis (€102.6 million, or 56% of sales), despite sharply...

               Paris, January 24, 2022                                            Disclosure of transactions in own shares From January 17 to January 21, 2022 Within the framework of the authorization granted by the General Meeting of VINCI SA of April 8, 2021 to trade in its shares and in accordance with the regulations relating to share buybacks, VINCI SA (LEI:213800WFQ334R8UXUG83) declares the purchases of treasury shares below (FR0000125486), carried out from January 17 to January 21, 2022 : I- Aggregate presentation by day and by marketIssuer’s name Date of transaction Identifying code of financial instrument Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares in Euro Market (MIC code)VINCI 17/01/2022 FR0000125486 38146 98,2427 XPARVINCI 17/01/2022 FR0000125486 15666 98,2612 CEUXVINCI 17/01/2022 FR0000125486 3226 98,2822 TQEXVINCI 17/01/2022 FR0000125486 2962 98,2775 AQEUVINCI 18/01/2022 FR0000125486 45700 97,5407 XPARVINCI 18/01/2022 FR0000125486 17200 97,5724 CEUXVINCI 18/01/2022 FR0000125486 3700 97,5729 TQEXVINCI 18/01/2022 FR0000125486 3400 97,5875 AQEUVINCI 19/01/2022 FR0000125486 37696 98,0295 XPARVINCI 19/01/2022 FR0000125486 15816 98,0730 CEUXVINCI 19/01/2022 FR0000125486 3386 98,0698 TQEXVINCI 19/01/2022 FR0000125486 3102 98,0942 AQEUVINCI 20/01/2022 FR0000125486 38547 98,6871 XPARVINCI 20/01/2022 FR0000125486 15851 98,6823 CEUXVINCI 20/01/2022 FR0000125486 2836 98,6899 TQEXVINCI 20/01/2022 FR0000125486 2766 98,6973 AQEUVINCI 21/01/2022 FR0000125486 47970 97,9584 XPARVINCI 21/01/2022 FR0000125486 17821 97,9085 CEUXVINCI 21/01/2022 FR0000125486 3671 97,9148 TQEXVINCI 21/01/2022 FR0000125486 3504 97,9103 AQEU               TOTAL 322...

Lannion, January 24, 2022 – 5:45pm LUMIBIRD MAINTAINS DOUBLE-DIGIT PRO FORMA GROWTH1 IN 2021 The LUMIBIRD Group, the European leader for laser technologies, is reporting 28% full-year consolidated revenue growth for 2021, up to €162.5m. In the fourth quarter, revenues came to nearly €50m, exceeding the record set in the fourth quarter of 2020. This enables the Group to confirm double-digit pro forma growth1 of +10%. Consolidated revenues (unaudited)Revenues (€m) 2021 2020 Reported change pro forma 2020 1 Pro forma 1 changeFirst quarter 33.8 21.9 +54% 32.7 +3.2%Second quarter 41.7 23.9 +75% 33.8 +23%Third quarter 37.2 32.7 +13% 32.8 +13%Fourth quarter 49.8 48.2 +3% 48.3 +3%12 months 162.5 126.7 +28% 147.7 +10%of which          Photonics...

NACON                                                Press release       Lesquin, 24 January 2022 – 18:00    RETURN TO GROWTH FOR Q3 2021-22 (+5,2%) CONFIRMATION OF 2021/22 & 2022/23 TARGETSIFRS – M€ 2021/222020/21ChangeSales1st Quarter (April-June)33.7 38.0 -11.3%2nd Quarter (July-September)39.3 48.6 -19.1%3rd Quarter (Oct.-Dec.) (1) 51.2 48.6 +5.2%       Games 14.3 13.8 +3.4%Accessories 34.9 32.5 +7.4%Others(2) 2.0 2.3 -14.4%       Cumulative 9 months (April-Dec.) (1) 124.2 135.3 -8.2%       Games 41.6 46.6 -10.9%Accessories 78.7 84.1 –6.4%Others (2) 4.0 4.5 -12.2%       (1)Non audited data      (2)Mobile and Audio sales      Q3 sales rebound to 51.2 M€ i.e. +5.2% In Q3 2021/22, Nacon returned to growth after two quarters which had been impacted by a very...

CATSKILL, N.Y., Jan. 24, 2022 (GLOBE NEWSWIRE) — Greene County Bancorp, Inc. (the “Company”) (NASDAQ: GCBC), the holding company for The Bank of Greene County and its subsidiary Greene County Commercial Bank, today reported net income for the three and six months ended December 31, 2021, which is the second quarter of the Company’s fiscal year ending June 30, 2022. Net income for the three and six months ended December 31, 2021 was $6.9 million, or $0.81 per basic and diluted share, and $14.0 million, or $1.64 per basic and diluted share, respectively, as compared to $6.2 million, or $0.73 per basic and diluted share, and $11.1 million, or $1.30 per basic and diluted share, for the three and six months ended December 31, 2020, respectively. Highlights:Net Income: $14.0 million for the six months ended December 31, 2021 Total...

NEW YORK, Jan. 24, 2022 (GLOBE NEWSWIRE) — Tiziana Life Sciences Ltd. (Nasdaq: TLSA) announced that its Board of Directors has today authorized the Company’s management to implement a stock repurchase program for up to $5 million of the Company’s common shares at any time. The term of the board authorization is until December 31, 2022. The repurchase program may be suspended or discontinued at any time and will be funded using the Company’s working capital. Executive Chairman Gabriele Cerrone commented, “This announcement demonstrates our confidence in Tiziana’s business and the growth opportunities we see over the long term. We believe this is an attractive use of capital, and based on the strength of our balance sheet, we continue to see ample opportunity to invest and grow our business.” About Tiziana Life Sciences Tiziana Life...

Two papers in The Lancet highlight one-year results from Roche’s phase III trials evaluating faricimab in neovascular or “wet” age-related macular (nAMD) and diabetic macular edema (DME) Across four studies, about half of eligible faricimab patients were able to go four months between treatments, and approximately three-quarters could be treated every three months or longer Reductions in central subfield thickness (CST) and resolution of intraretinal fluid consistently favoured faricimab over aflibercept in DME, and meaningful and comparable CST reductions were seen in nAMD in the first yearBasel, 24 January 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that The Lancet has published two papers highlighting one-year results from four pivotal phase III studies of faricimab, an investigational bispecific antibody, in...

Hamilton, BermudaJanuary 24, 2021 Flex LNG Ltd. (“Flex LNG” or the “Company”) will release its preliminary financial results for the fourth quarter of 2021 on Wednesday February 16, 2022 on or about 07:00 CET (1:00 a.m. EST). In connection with the earnings release, a webcast and conference call will be held at 15:00 CET (9:00 a.m. EST) the same day. In order to attend the webcast and/or conference call you may do one of the following: Attend by Webcast:Use to the follow link prior to the webcast: https://edge.media-server.com/mmc/p/42dfa2a2 Attend by Conference Call: Applicable dial-in telephone numbers are as follows: Norway: +47 21 56 30 15United Kingdom: +44 (0) 2071 928 338United Kingdom, local: 08444 819 752United Kingdom (toll free): 0800 279 6619United States: +1 646 741 3167United States (toll free): +1 877...